1. Rock K, McArdle O, Forde P, Dunne M, Fitzpatrick D, O'Neill B, et al. A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival? Br J Radiol (2012) 85(1017):e729-33. Epub 2012/01/05. doi: 10.1259/bjr/83796755. PubMed PMID: 22215883; PubMed Central PMCID: PMCPMC3487092.
2. Young RM, Jamshidi A, Davis G, Sherman JH. Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med (2015) 3(9):121. Epub 2015/07/25. doi: 10.3978/j.issn.2305-5839.2015.05.10. PubMed PMID: 26207249; PubMed Central PMCID: PMCPMC4481356.
3. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol (2019) 21(Supplement_5):v1-v100. Epub 2019/11/02. doi: 10.1093/neuonc/noz150. PubMed PMID: 31675094; PubMed Central PMCID: PMCPMC6823730.
4. Biomarkers and therapeutic advances in glioblastoma multiforme;Sasmita;Asia-Pac J. Clin. Oncol.,2018
5. Klughammer J, Kiesel B, Roetzer T, Fortelny N, Nemc A, Nenning KH, et al. The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nat Med (2018) 24(10):1611-24. Epub 2018/08/29. doi: 10.1038/s41591-018-0156-x. PubMed PMID: 30150718; PubMed Central PMCID: PMCPMC6181207.